Mesorectal excision with or without lateral lymph node dissection for clinical stage II/III lower rectal cancer (JCOG0212): a multicenter, randomized controlled, noninferiority trial. Ann Surg 2017; 266: 201-207.

Published: 6th October 2017

Authors: Fujita S, Mizusawa J, Kanemitsu Y, Ito M, Kinugasa Y, Komori K et al.


The addition of lateral lymph node dissection reduced the number of patients with local tumour recurrence 7.4 versus 12.6 per cent (P= 0.024) but five year relapse-free survival and overall survival rates were similar in this study that included 701 patients.

Pubmed Link

Your comments